In a huge step towards the evolution of medical research, Mikrobiomik, the pioneer company in the human microbiome, has confirmed a capital increase of 1.1 million euros. This milestone happens thanks to the exclusive contribution of its current partners, who are determined to accomplish their initial mission: to launch their investigational biological drug, MBK 01, on the European market.